Table A3.
Unit drug costs.
| Resource | Unit Cost | Reference |
|---|---|---|
| Rituximab 100 mg | CAD 482.31 | Ontario Exceptional Access Program [47] |
| Bendamustine 25 mg | CAD 312.50 | pCODR Economic Guidance Report for Bendamustine [48] |
| Lenalidomide 25 mg | CAD 424.00 | Ontario Exceptional Access Program [47] |
| Lenalidomide 20 mg | CAD 403.00 | Ontario Exceptional Access Program [47] |
| Lenalidomide 15 mg | CAD 382.00 | Ontario Exceptional Access Program [47] |
| Lenalidomide 10 mg | CAD 361.00 | Ontario Exceptional Access Program [47] |
| Lenalidomide 5 mg | CAD 340.00 | Ontario Exceptional Access Program [47] |
| Lenalidomide 2.5 mg | CAD 329.00 | Ontario Exceptional Access Program [47] |
| Bortezomib 3.5 mg | CAD 1402.42 | pCODR Economic Guidance Report for Daratumumab [49] |
| Anthracycline 1 mg | CAD 5.05 | pCODR Economic Guidance Report for Pertuzumab-Trastuzumab [50] |
| Fludarabine 50 mg | CAD 255.00 | pCODR Economic Guidance Report for Ibrutinib [5] |
| Cyclophosphamide 1g | CAD 52.06 | pCODR Economic Guidance Report for Ibrutinib [5] |
| Ibrutinib 140 mg | CAD 97.60 | Ontario Exceptional Access Program [47] |
| Dexamethasone 4 mg | CAD 0.30 | Ontario Drug Benefit Formulary [66] |
| Tocilizumab 20 mg | CAD 182.80 | Ontario Exceptional Access Program [47] |
Abbreviations: MoHLTC, Ministry of Health and Long-Term Care; pCODR, pan-Canadian Oncology Drug Review.